Savara Inc. (SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, is progressing toward a key regulatory milestone for its lead investigational asset, MOLBREEVI.
MOLBREEVI is a non-glycosylated form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in inhaled formulation being developed as a potential treatment option for autoimmune pulmonary alveolar proteinosis (aPAP).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com